About this Research Topic
Epidemiological studies have shown an increase in global cancer cases annually. Simultaneously, great progress has been made in tumour immunotherapy and the development of immunotherapy drugs. In addition, Pan-cancer analysis has facilitated exploration of related pathways and molecular mechanisms in tumours, also in relation to prognosis. However, there is no definitive treatment for cancer and a strong focus still lies on identifying new potential therapeutic targets for cancer therapy in addition to traditional surgical therapy.
In recent years, cancer immunotherapy (CIT) has made rapid progress in the treatment of various types of cancers, including immune checkpoint therapy, CAR T cell therapy, cancer vaccine, and tumor neoantigen therapy, which have already been applied in the clinic. Although immunotherapy has been applied to various tumors, its ultimate efficacy is still limited, and can cause a variety of side effects.
It has also been shown that the complex interplay between tumor cells and the tumor microenvironment (TME) drives cancer development. Infiltrating immune cells are a crucial component of the TME and correlation between them with patient prognosis can yield important biomarkers to support patient prognoses, as well as their response to chemotherapy, radiotherapy or immunotherapy.
This Research Topic encourages manuscripts addressing immune infiltration and immunotherapy in various cancers. Specific topics include, but are not limited to:
• Identification of predictive biomarker to assess the response to therapy approaches
• Combining Immunotherapy and Targeted Therapies in various Cancer Treatment
• Gene expression and immune infiltration in various cancer
• Immune infiltration-associated lncRNAs/RNAs/siRNA/snRNA - expression and function, to improve immunotherapy response
• (Intra)-Tumor Heterogeneity and Immune Infiltration in cancer
• Predicting Immune escape and Immunotherapy in cancer
• Tumor Immuno-Microenvironment and Immune infiltration / immunotherapy
• New area in Immunotherapy: tumor-infiltrating lymphocyte
• Precision-targeted technologies and Immunotherapy
In recent years, cancer immunotherapy (CIT) has made rapid progress in the treatment of various types of cancers, including immune checkpoint therapy, CAR T cell therapy, cancer vaccine, and tumor neoantigen therapy, which have already been applied in the clinic. Although immunotherapy has been applied to various tumors, its ultimate efficacy is still limited, and can cause a variety of side effects.
It has also been shown that the complex interplay between tumor cells and the tumor microenvironment (TME) drives cancer development. Infiltrating immune cells are a crucial component of the TME and correlation between them with patient prognosis can yield important biomarkers to support patient prognoses, as well as their response to chemotherapy, radiotherapy or immunotherapy.
This Research Topic encourages manuscripts addressing immune infiltration and immunotherapy in various cancers. Specific topics include, but are not limited to:
• Identification of predictive biomarker to assess the response to therapy approaches
• Combining Immunotherapy and Targeted Therapies in various Cancer Treatment
• Gene expression and immune infiltration in various cancer
• Immune infiltration-associated lncRNAs/RNAs/siRNA/snRNA - expression and function, to improve immunotherapy response
• (Intra)-Tumor Heterogeneity and Immune Infiltration in cancer
• Predicting Immune escape and Immunotherapy in cancer
• Tumor Immuno-Microenvironment and Immune infiltration / immunotherapy
• New area in Immunotherapy: tumor-infiltrating lymphocyte
• Precision-targeted technologies and Immunotherapy
Keywords: immune infiltration, immunotherapy, cancer, tumor microenvironment, targeted therapy
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
